WILLIAM DAVIS: Open Payments
NPI 1659581270 · PAW PAW, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$985 in 28 payments from 11 companies in 2025. Trend: 2023 $807 · 2024 $1,432 · 2025 $985
Food & beverage: $985
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 5 | $275 |
| Neurocrine BioSciences, Inc. | 6 | $181 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $157 |
| Axsome Therapeutics, Inc. | 2 | $144 |
| Alkermes, Inc. | 3 | $55 |
| Teva Pharmaceuticals USA, Inc. | 2 | $54 |
| Supernus Pharmaceuticals, Inc. | 2 | $44 |
| Vanda Pharmaceuticals Inc. | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
Products named: COBENFY, INGREZZA, CAPLYTA, Auvelity, ARISTADA, Qelbree, AUSTEDO XR, UZEDY.
Industry payments across MI — which companies pay providers there.
